Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720954 | 0.90 | BCHE (0.30) | TSHRBCHE | |
| SCHEMBL2460446 | 0.87 | ELANE (0.37) | ELANELMNABCHEMAPT | |
| SCHEMBL2462799 | 0.85 | BCHE (0.31) | BCHEMAPT | |
| SCHEMBL2459368 | 0.84 | KCNH2 (0.38) | ELANECYP1A2LMNACYP2D6CYP2C19 | |
| SCHEMBL2456300 | 0.83 | CYP1A2 (0.31) | CYP1A2CYP2A6 | |
| SCHEMBL2459934 | 0.82 | ELANE (0.38) | ELANELMNABCHEMAPT | |
| SCHEMBL2456814 | 0.81 | ELANE (0.35) | ELANECYP1A2LMNACYP2D6CYP2C19 | |
| SCHEMBL4722542 | 0.80 | ELANE (0.37) | ELANELMNABCHEMAPT | |
| SCHEMBL2456330 | 0.80 | KCNH2 (0.36) | ELANECYP1A2LMNACYP2D6CYP2C19 | |
| SCHEMBL6553704 | 0.78 | TSHR (0.39) | TSHRCYP2C19ACHECNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116703-A1 | 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field | NEUROSEARCH A/S | 2004-06-17 | — | — | US | claimed |
| EP-1133494-B1 | 8-AZABICYCLO 3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES | NEUROSEARCH AS (DK) | 2004-02-18 | — | — | EP | claimed |
| US-6680328-B2 | CHOLINERGIC LIGANDS OF NICOTINIC ACETYL CHOLINE RECEPTORS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, SMOOTH MUSCLE CONTRACTION DISORDERS, ENDOCRINE DISEASES/DISORDERS, NEURODEGENERATION, INFLAMMATION, PAIN, AND DRUG WITHDRAWAL | NEUROSEARCH A/S (DK) | 2004-01-20 | — | — | US | claimed |
| US-20020035122-A1 | 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives | ANIONA APS (DK) | 2002-03-21 | — | — | US | claimed |
| EP-1133494-A1 | 8-AZABICYCLO 3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES | NEUROSEARCH A/S (DK) | 2001-09-19 | — | — | EP | claimed |
| WO-2000032600-A1 | 8-AZABICYCLO[3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES | NEUROSEARCH A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| EP-2524686-B1 | PIGMENTATION-PREVENTING OR -AMELIORATING AGENT | POLA CHEM IND INC (JP) | 2017-06-21 | — | — | EP | disclosed |
| EP-2514402-B1 | PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION | POLA CHEM IND INC (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-9414998-B2 | Preventing or ameliorating agent for pigmentation | POLA CHEMICAL INDUSTRIES INC. (JP) | 2016-08-16 | — | — | US | disclosed |
| US-9066914-B2 | Prophylactic or ameliorating agent for pigmentation | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-06-30 | — | — | US | disclosed |
| US-20140322150-A1 | PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-10-30 | — | — | US | disclosed |
| EP-2524686-A1 | PIGMENTATION-PREVENTING OR -AMELIORATING AGENT | Pola Chemical Industries Inc. (JP) | 2012-11-21 | — | — | EP | disclosed |
| US-20120282203-A1 | PROPHYLACTIC OR AMELIORATING AGENT FOR PIGMENTATION | POLA CHEMICAL INDUSTRIES INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| US-5035969-A | And a compound in a photoconductive layer on a support; high potential stability, durability | FUJI PHOTO FILM CO., LTD. (JP) | 1991-07-30 | — | — | US | disclosed |
| US-4985323-A | Photoconductor, Sensitizer, Amide | FUJI PHOTO FILM CO., LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| US-4943681-A | PHTHALOCYANINE COMPLEX, HIGH SENSITIVITY, LASERS | TOYO INK MANUFACTURING CO., LTD. (JP) | 1990-07-24 | — | — | US | disclosed |
| EP-0376745-A2 | Optical recording medium and process for the production thereof | TOYO INK MANUFACTURING CO., LTD. (JP) | 1990-07-04 | — | — | EP | disclosed |
| US-4411812-A | Dichroic liquid crystal compositions made with asymmetric tris-azo dyes | GENERAL ELECTRIC COMPANY (US) | 1983-10-25 | — | — | US | disclosed |
| US-4411812-A | Dichroic liquid crystal compositions made with asymmetric tris-azo dyes | GENERAL ELECTRIC COMPANY (US) | 1983-10-25 | — | — | US | disclosed |
| US-4256458-A | DIMERIC PYRIDINIUM DYES | BASF AKTIENGESELLSCHAFT (DE) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035122-A1 | 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives | CHRNA2, CHRNA7, CHRNA10 | ACP1 4220/4885TSHR 216/4885ELANE 1312/4885 |
| US-20120282203-A1 | PROPHYLACTIC OR AMELIORATING AGENT FOR PIGMENTATION | TYR, MC1R, NQO1 | ACP1 2998/4885TSHR 2578/4885ELANE 691/4885 |
| US-20140322150-A1 | PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION | TYR, MC1R, MITF | ACP1 2054/4885TSHR 1691/4885ELANE 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.